HALEOSLABS vs INDOCO: Stock Comparison

Haleos Labs Limited vs Indoco Remedies Limited

Live data: 22 July 2026, 2:53 PM IST • Source: NSE and company filings

Indoco Remedies Limited is the larger company by market capitalisation. Haleos Labs Limited shows a higher ROE, a higher dividend yield and lower leverage, while Indoco Remedies Limited shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Haleos Labs Limited and Indoco Remedies Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, HALEOSLABS is more favourable on 8 of 13 scored metrics and INDOCO on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
INDOCO is the larger company
₹2,160 Cr vs ₹484 Cr
P/E Ratio
INDOCO has a lower P/E
-23.83x vs 27.94x
P/B Ratio
HALEOSLABS has a lower P/B
2.27x vs 2.41x
EPS
HALEOSLABS has higher earnings per share
₹57.3 vs ₹-10.71
Dividend Yield
HALEOSLABS has a higher dividend yield
0.1% vs 0.08%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs 0%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
21.9% vs -15.7%
Qtr Profit Growth
INDOCO has stronger quarterly profit growth
39% vs -85.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricHALEOSLABSINDOCO
SectorHealthcare
IndustryPharmaceuticals

Price

MetricHALEOSLABSINDOCO
Live Price₹1,522.4₹233.99
Day Change-3.09%-4.82%
Volume28171,688
52-Week High₹1,774₹336
52-Week Low₹1,181₹162.19
Distance from 52W High-14.18%-30.36%

Valuation

MetricHALEOSLABSINDOCO
Market Cap₹484 Cr₹2,160 Cr
P/E Ratio27.94x-23.83x
P/B Ratio2.27x2.41x
EPS₹57.3₹-10.71
Book Value₹706₹111.55
Dividend Yield0.1%0.08%

Growth

MetricHALEOSLABSINDOCO
Revenue Growth (TTM YoY)0%21.9%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-15.7%21.9%
Qtr Profit Growth-85.2%39%

Profitability & Leverage

MetricHALEOSLABSINDOCO
ROE8.44%-9.42%
ROCE9.91%0.93%
Net Margin5.33%-5.31%
Operating Margin13.4%7.68%
Debt to Equity0.52x1.16x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricHALEOSLABSINDOCO
Promoter Holding72.11%58.86%
FII Holding0%1.27% 0.33 pp
DII Holding0.31% 0.01 pp17.68% 0.47 pp
Public Holding27.58% 0.02 pp22.04% 0.14 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Haleos Labs Limited and Indoco Remedies Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.